TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06841354: A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1000 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06841354 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06841354 Rescue Dossier →